Modified bispecific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 show higher ADCC potential and in vivo anti-tumor response

Authors

• Ashley Gelin, The University of Texas MD Anderson Cancer CenterFollow
• Coline Agnes Couillault, The University of Texas MD Anderson Cancer Center
• Anupallavi Srinivasamani, The University of Texas MD Anderson Cancer Center
• Qinying Liu, The University of Texas MD Anderson Cancer Center
• Michael Andrew Curran, The University of Texas MD Anderson Cancer Center

Files

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston

Keywords

Bispecific Antibodies; Monospecific Antibodies; ADCC; Programmed Death Ligand 1

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Program Affiliation

CPRIT-CURE Summer Undergraduate Program

Recommended Citation

Gelin, Ashley; Couillault, Coline Agnes; Srinivasamani, Anupallavi; Liu, Qinying; and Curran, Michael Andrew, "Modified bispecific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 show higher ADCC potential and in vivo anti-tumor response" (2021). Summer Experience 2021. 55.
https://openworks.mdanderson.org/sumexp21/55